© 1991 Oxford University Press
research-article |
Effects of monoterpenoids on in vivo DMBA-DNA adduct formation and on phase I hepatic metabolizing enzymes
1Department of Human Oncology, University of Wisconsin-Madison 600 Highland Ave, Madison, WI 53792, USA
2Department of Pharmacology, University of Wisconsin-Madison 600 Highland Ave, Madison, WI 53792, USA
3The Environmental Toxicology Center, University of Wisconsin-Madison 600 Highland Ave, Madison, WI 53792, USA
4To whom correspondence should be addressed
We have previously demonstrated the anticarcinogenk effects of monocyclic monoterpenes such as limonene when given during the initiation phase of 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary cancer in Wistar-Furth (WF) rats. Here we investigated the possible mechanisms for this chemoprevention activity including limonene's effects on DMBA-DNA adduct formation and hepatic metabolism of DMBA. Twenty-four hours after carcinogen administration, there were {small tilde}50% of the total DMBA-DNA adducts found in control animals formed in the liver, spleen, kidney and lung of limonene-fed animals. While circulating levels of DMBA and/or its metabolites were not different in control and limonene-fed rats, there was a 2.3-fold increase in DMBA and/or DMBA-derived metabolites in the urine of the limonene-fed animals. Studies of the effects of limonene and sobrerol, a hydroxylated monocyclic monoterpenoid with increased chemoprevention activity, on phase I metabolizing enzymes revealed that these terpenoids modulated cytochrome P450 (CYP) and epoxide hydratase (EH) activity. The 5% limonene diet increased total CYP to the same extent as phenobarbital (PB) treatment when compared to control, while 1% sobrerol (isoeffective in chemoprevention to 5% limonene) did not. However, both 5% limonene and 1% sobrerol diets greatly increased the levels of microsomal EH protein and associated hydrating activities towards benzo[a]pyrene 4,5-oxide when compared to control and PB treatment. These changes also modified the rate and regioselectivity of in vitro microsomal DMBA metabolism when compared to PB treatment or control. Identification of the specific isoforms of CYP induced by these terpenoids was performed using antibodies to CYP isozymes in Western blot analysis and inhibition studies of microsomal DMBA metabolism. Five per cent limonene was more effective than 1% sobrerol at increasing the levels of members of the CYP2B and 2C families but was equally effective at increasing EH. Furthermore, both terpenoid diets caused increased formation of the proximate carcinogen, DMBA 3,4-dihydrodiol. While these terpene-induced changes in hepatic CYP and EH do not explain the anticarcinogenic mechanism of these chemopreventive agents, or the ability of limonene systemically to reduce DMBA-DNA binding, they do reveal novel and selective induction mechanisms of hepatic enzymes.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. V. Nesterova and Y. S. Cho-Chung Antisense Protein Kinase A RI{alpha} Inhibits 7,12-Dimethylbenz(a)anthracene-Induction of Mammary Cancer: Blockade at the Initial Phase of Carcinogenesis Clin. Cancer Res., July 1, 2004; 10(13): 4568 - 4577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H-H. S. Chow, D. Salazar, and I. A. Hakim Pharmacokinetics of Perillic Acid in Humans after a Single Dose Administration of a Citrus Preparation Rich in d-Limonene Content Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1472 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lluria-Prevatt, J. Morreale, J. Gregus, D. S. Alberts, F. Kaper, A. Giaccia, and M. B. Powell Effects of Perillyl Alcohol on Melanoma in the TPras Mouse Model Cancer Epidemiol. Biomarkers Prev., June 1, 2002; 11(6): 573 - 579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Shi and M. N. Gould Induction of cytostasis in mammary carcinoma cells treated with the anticancer agent perillyl alcohol Carcinogenesis, January 1, 2002; 23(1): 131 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Low-Baselli, W. W. Huber, M. Kafer, K. Bukowska, R. Schulte-Hermann, and B. Grasl-Kraupp Failure to demonstrate chemoprevention by the monoterpene perillyl alcohol during early rat hepatocarcinogenesis: a cautionary note Carcinogenesis, October 1, 2000; 21(10): 1869 - 1877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Marczylo, S. Arimoto-Kobayashi, and H. Hayatsu Protection against Trp-P-2 mutagenicity by purpurin: mechanism of in vitro antimutagenesis Mutagenesis, May 1, 2000; 15(3): 223 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Ripple, M. N. Gould, R. Z. Arzoomanian, D. Alberti, C. Feierabend, K. Simon, K. Binger, K. D. Tutsch, M. Pomplun, A. Wahamaki, et al. Phase I Clinical and Pharmacokinetic Study of Perillyl Alcohol Administered Four Times a Day Clin. Cancer Res., February 1, 2000; 6(2): 390 - 396. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. L. Crowell Prevention and Therapy of Cancer by Dietary Monoterpenes J. Nutr., March 1, 1999; 129(3): 775 - 775. [Abstract] [Full Text]
|
|